Cargando…

A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine

BACKGROUND: Asthma is an independent risk factor for invasive pneumococcal disease; however, the immune response of adult asthma patients to pneumococcal vaccination is unknown. We explore the serologic response of patients with moderate to severe asthma to the 23-valent pneumococcal polysaccharide...

Descripción completa

Detalles Bibliográficos
Autores principales: Laratta, C. R., Williams, K., Vethanayagam, D., Ulanova, M., Vliagoftis, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463404/
https://www.ncbi.nlm.nih.gov/pubmed/28596792
http://dx.doi.org/10.1186/s13223-017-0200-2
_version_ 1783242702606827520
author Laratta, C. R.
Williams, K.
Vethanayagam, D.
Ulanova, M.
Vliagoftis, H.
author_facet Laratta, C. R.
Williams, K.
Vethanayagam, D.
Ulanova, M.
Vliagoftis, H.
author_sort Laratta, C. R.
collection PubMed
description BACKGROUND: Asthma is an independent risk factor for invasive pneumococcal disease; however, the immune response of adult asthma patients to pneumococcal vaccination is unknown. We explore the serologic response of patients with moderate to severe asthma to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). METHODS: Seventeen moderate to severe adult asthma patients that had not been vaccinated against pneumococcus over the 5 previous years were prospectively recruited from a tertiary care asthma clinic. Serum was analyzed for the presence of antibodies to five capsular polysaccharide (CP) antigens (6B, 9V, 19A, 19F, 23F) before and 4 weeks after PPSV23 vaccination. RESULTS: There was a wide variability in baseline anti-CP antibody concentrations. Other than for serotype 19A, our patients frequently have baseline anti-CP antibody concentrations below 1 µg/mL (35% for serotype 19F, 41% for serotypes 9V and 23F, and 59% for serotype 6B). All post-vaccination geometric mean antibody concentrations were significantly higher than baseline. In the 31 tests where the baseline antibody concentration was <1 µg/mL, 77.4% had at least a twofold increase post-vaccination. Despite this, a large proportion of post-vaccination anti-CP antibody concentrations remained <1 µg/mL (51.6% of tests). Nine patients had at least one anti-CP antibody concentration <1 µg/mL post-vaccination. There was no difference between these patients and the remaining eight patients in demographic or clinical variables. CONCLUSIONS: Patients with moderate to severe asthma have variable baseline and low post-vaccination antibody concentrations to common CP antigens included in the PPSV23 vaccine. The clinical relevance of these observations remains to be determined since the threshold concentration in adults required for clinical protection from invasive pneumococcal disease is uncertain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13223-017-0200-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5463404
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54634042017-06-08 A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine Laratta, C. R. Williams, K. Vethanayagam, D. Ulanova, M. Vliagoftis, H. Allergy Asthma Clin Immunol Research BACKGROUND: Asthma is an independent risk factor for invasive pneumococcal disease; however, the immune response of adult asthma patients to pneumococcal vaccination is unknown. We explore the serologic response of patients with moderate to severe asthma to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). METHODS: Seventeen moderate to severe adult asthma patients that had not been vaccinated against pneumococcus over the 5 previous years were prospectively recruited from a tertiary care asthma clinic. Serum was analyzed for the presence of antibodies to five capsular polysaccharide (CP) antigens (6B, 9V, 19A, 19F, 23F) before and 4 weeks after PPSV23 vaccination. RESULTS: There was a wide variability in baseline anti-CP antibody concentrations. Other than for serotype 19A, our patients frequently have baseline anti-CP antibody concentrations below 1 µg/mL (35% for serotype 19F, 41% for serotypes 9V and 23F, and 59% for serotype 6B). All post-vaccination geometric mean antibody concentrations were significantly higher than baseline. In the 31 tests where the baseline antibody concentration was <1 µg/mL, 77.4% had at least a twofold increase post-vaccination. Despite this, a large proportion of post-vaccination anti-CP antibody concentrations remained <1 µg/mL (51.6% of tests). Nine patients had at least one anti-CP antibody concentration <1 µg/mL post-vaccination. There was no difference between these patients and the remaining eight patients in demographic or clinical variables. CONCLUSIONS: Patients with moderate to severe asthma have variable baseline and low post-vaccination antibody concentrations to common CP antigens included in the PPSV23 vaccine. The clinical relevance of these observations remains to be determined since the threshold concentration in adults required for clinical protection from invasive pneumococcal disease is uncertain. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13223-017-0200-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-07 /pmc/articles/PMC5463404/ /pubmed/28596792 http://dx.doi.org/10.1186/s13223-017-0200-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Laratta, C. R.
Williams, K.
Vethanayagam, D.
Ulanova, M.
Vliagoftis, H.
A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title_full A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title_fullStr A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title_full_unstemmed A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title_short A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
title_sort case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463404/
https://www.ncbi.nlm.nih.gov/pubmed/28596792
http://dx.doi.org/10.1186/s13223-017-0200-2
work_keys_str_mv AT larattacr acaseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT williamsk acaseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT vethanayagamd acaseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT ulanovam acaseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT vliagoftish acaseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT larattacr caseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT williamsk caseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT vethanayagamd caseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT ulanovam caseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine
AT vliagoftish caseseriesevaluatingtheserologicalresponseofadultasthmapatientstothe23valentpneumococcalpolysaccharidevaccine